Literature DB >> 8533838

Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies.

M Vainzof1, M R Passos-Bueno, N Man, M Zatz.   

Abstract

While present in the surface membrane of embryonic muscle fibers, in adult normal muscle fibers, utrophin is restricted to the motor endplate and cells of blood vessel walls. However, the observation that utrophin is maintained in the extrajunctional plasma membrane in Duchenne (DMD) and in mdx muscle fibers has led to the suggestion that excess utrophin might compensate for dystrophin deficiency in the Xp21 muscular dystrophies. In order to detect an inverse correlation of utrophin presence and clinical severity, we have assessed utrophin distribution and quantity in DMD and Becker (BMD) patients of different ages and stages of clinical severity. All patients showed a positive discontinuous immunolabeling of utrophin on the sarcolemma, staining equally small and large muscle fibers, indicating that immature characteristics are maintained in such fibers. On Western blot, utrophin bands with concentrations 2- to 10-fold greater than in normal controls were detected in all DMD/BMD patients. However, no negative correlation was found between the amount of utrophin and the severity of clinical course, implying that the detectable utrophin levels in these patients did not compensate for dystrophin deficiency. In a DMD patient with growth hormone (GH) deficiency and a BMD-like clinical course, utrophin levels were comparable to the other typical DMD cases, which reinforces the hypothesis that the observed increase in utrophin is apparently not responsible for a milder clinical course in some patients with Xp21 muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8533838     DOI: 10.1002/ajmg.1320580403

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

Review 1.  Mechanisms of resistance to pathogenesis in muscular dystrophies.

Authors:  J P Infante; V A Huszagh
Journal:  Mol Cell Biochem       Date:  1999-05       Impact factor: 3.396

2.  Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice.

Authors:  Dejia Li; Chun Long; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2009-01-08       Impact factor: 6.150

3.  Muscle structure influences utrophin expression in mdx mice.

Authors:  Glen B Banks; Ariana C Combs; Guy L Odom; Robert J Bloch; Jeffrey S Chamberlain
Journal:  PLoS Genet       Date:  2014-06-12       Impact factor: 5.917

Review 4.  Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.

Authors:  Simon Guiraud; Huijia Chen; David T Burns; Kay E Davies
Journal:  Exp Physiol       Date:  2015-08-04       Impact factor: 2.969

Review 5.  Recent insights into neuromuscular junction biology in Duchenne muscular dystrophy: Impacts, challenges, and opportunities.

Authors:  Sean Y Ng; Vladimir Ljubicic
Journal:  EBioMedicine       Date:  2020-10-08       Impact factor: 8.143

6.  Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies.

Authors:  Narinder Janghra; Jennifer E Morgan; Caroline A Sewry; Francis X Wilson; Kay E Davies; Francesco Muntoni; Jonathon Tinsley
Journal:  PLoS One       Date:  2016-03-14       Impact factor: 3.240

7.  Neuromuscular disorders: genes, genetic counseling and therapeutic trials.

Authors:  Mayana Zatz; Maria Rita Passos-Bueno; Mariz Vainzof
Journal:  Genet Mol Biol       Date:  2016 Jul-Sep       Impact factor: 1.771

8.  Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.

Authors:  Simon Guiraud; Benjamin Edwards; Sarah E Squire; Lee Moir; Adam Berg; Arran Babbs; Nesrine Ramadan; Matthew J Wood; Kay E Davies
Journal:  Hum Mol Genet       Date:  2019-01-15       Impact factor: 6.150

9.  Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.

Authors:  Patricia Soblechero-Martín; Andrea López-Martínez; Laura de la Puente-Ovejero; Ainara Vallejo-Illarramendi; Virginia Arechavala-Gomeza
Journal:  Neuropathol Appl Neurobiol       Date:  2021-06-04       Impact factor: 8.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.